Nexgel (NXGL) Cash & Equivalents (2019 - 2025)

Nexgel's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Cash & Equivalents fell 41.45% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 41.45% YoY) and the FY2025 annual result came in at $1.1 million, down 41.45% from the prior year.
• Cash & Equivalents was $1.1 million for Q4 2025 at Nexgel, up from $938000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $13.4 million in Q4 2021 and bottomed at $382000.0 in Q2 2021.
• A 5-year average of $2.7 million and a median of $1.2 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 41618.75% — and 2023, when it tumbled 92.52%.
• Nexgel's Cash & Equivalents stood at $13.4 million in 2021, then plunged by 91.75% to $1.1 million in 2022, then jumped by 145.23% to $2.7 million in 2023, then plunged by 33.07% to $1.8 million in 2024, then slumped by 41.45% to $1.1 million in 2025.
• Business Quant data shows NXGL's Cash & Equivalents at $1.1 million in Q4 2025, $938000.0 in Q3 2025, and $725000.0 in Q2 2025.